

FORM PTO-1449
(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.: PRMG-06684

Serial No.: 09/99692

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

Applicant: John W. Shultz *et al.*

Filing Date: 02 APR 26 PM 2:39

Group Art Unit:

(37 CFR § 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
VAC	1	4,683,195	11/27/90	Mullis <i>et al.</i>	435	6	2/7/86
	2	4,683,202	11/27/90	Mullis	435	91	10/25/85
	3	4,965,188	10/23/90	Mullis <i>et al.</i>	435	6	6/17/87
	4	5,496,546	3/5/96	Wang <i>et al.</i>	424	78.36	2/23/94
	5	5,705,188	1/6/98	Junichi <i>et al.</i>	424	450	10/10/95
	6	5,776,690	7/7/98	Vojdani <i>et al.</i>	435	6	10/7/96

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
						Yes	No
✓	7 1	WO 97/30731	PCT				
✓	8 2	WO 93/08291	PCT				
✓	9 3	EP 1 050 587 A2	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

✓	10	Badet <i>et al.</i> , PNAS, 86:8427 [1989]. This reference is not be supplied at this time but will be supplied as soon as possible.
	11	Wechsel <i>et al.</i> , Anticancer Res., 19:1537 [1999]
	12	Montero <i>et al.</i> , Clin. Cancer Res., 5:3722 [1999]
	13	Hartmann <i>et al.</i> , Cancer Res., 59:1578 [1999]
	14	Miyake <i>et al.</i> , Cancer, 86:316 [1999].
	15	Eberle <i>et al.</i> , Anticancer Res., 20:1679 [2000].
	16	Shimoyama and Kaminishi, J. Cancer Res. Clin. Oncol., 126:468 [2000].
	17	Barton <i>et al.</i> , Clin. Cancer Res., 3:1579 [1997].
	18	Gho <i>et al.</i> , Cancer Res., 57:3733 [1997]
	19	Gho and Chae, J. Biol. Chem., 272:24294 [1997]
	20	Piccoli <i>et al.</i> , PNAS, 95:4579 [1998]
	21	Olson <i>et al.</i> , PNAS, 92:442 [1995]
	22	Anderson and Young, Quantitative Filter Hybridization, in <i>Nucleic Acid Hybridization</i> [1985]. This reference is a book and will be supplied at the Examiner's request.
	23	Wetmur, Crit. Rev. Biochem. and Mol. Biol. 26:227-[1991]. This reference is not be supplied at this time but will be supplied as soon as possible.
	24	Delcardayre <i>et al.</i> , Protein Engineering, 8:261 [1995]. This reference is not be supplied at this time but will be supplied as soon as possible.
	25	Rahman <i>et al.</i> Anal. Chem., 68:134 [1996]. This reference is not be supplied at this time but will be supplied as soon as possible.
	26	Lloveras <i>et al.</i> , Clin. Cancer Res. 5:1125-1130 (1999). This reference is not be supplied at this time but will be supplied as soon as possible.
	27	Shein, Nat. Biotechnol. 15(6):529-36 (1997)

Examiner:

Anne Kr. Chakrabarti

Date Considered:

4/30/02

EXAMINER:


Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

M 6/04

RECEIVED
APR 29 2002
TECH CENTER 1600/2900

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: PRMG-06684	Serial No.: 09/995,912
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: John W. Shultz <i>et al.</i>	
				Filing Date: 11/28/01	Group Art Unit:
(37 CFR § 1.98(b))					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
28	Verselis <i>et al.</i> , Biochem Biophys Res Commun: 27:259(1):178-84 (1999)				
29	Leónidas <i>et al.</i> , J. Mol. Biol. 22:285(3):1209-33 (1999)				
30	Cockerill <i>et al.</i> , Int Rev Cytol 159:113-60 (1995)				
31	Schneider <i>et al.</i> , Cytogenet Cell Genet 59(4):264-7 (1992)				
32	Bertolini <i>et al.</i> , Br J Haematol 106(2):504-9 (1999)				
33	Chopra <i>et al.</i> , Cancer Invest 16(3):152-9 (1998)				
34	Olson <i>et al.</i> , Biochem Biophys Res Commun 26:242(3):480-3 (1998)				
35	RNase OUT™ Recombinant Ribonuclease Inhibitor, Life Technologies, http://order.lifetech.com/li_store...rderidentifier=ID966619090890572376			No Date Provided	
36	Poly(I)*Poly(C), Amersham Pharmacia Biotech, pg. 88				
37	Poly(I)*Poly(C), Amersham Pharmacia Biotech, CATS Tue, Aug 01 2000				
38	RNAguard Ribonuclease Inhibitor (Procine), http://www.apbiotech.com/stiboasp/showmodule.asp?nModuleid=4140			No Date Provided	
39	SUPERase-In: the ULtimate RNase Inhibitor, Ribonuclease Inhibitor PRotein (RIP) Is No Longer The Best Ribonuclease Inhibitor, http://www.ambion.com/suprasein/Page2.html			No Date Provided	
40	Wu <i>et al.</i> , Amer Soc for Biochem and Molecular Biol., Inc. 270:17476-17481 (1995)				
41	Hilleman, Journal of Infectious Diseases, 121:196-211 (1970)				
42	Field <i>et al.</i> , PNAS 58:1004-1010 (1967)				
43	Baugh <i>et al.</i> , Div. of Virus and Cell Biol Res., 1194-1198 (1971)				
44	Fehlmann <i>et al.</i> , Clinical Chemistry 39:368-396 (1993)				
45	Buolamwini, Chemical Biology 3:500-509 (1999)				
46	Levy <i>et al.</i> , Medical Sciences 62:357-361 (1969)				
47	Soncin <i>et al.</i> , J. of Biological Chemistry 272:9818-9824 (1997)				
48	Panganiban <i>et al.</i> , J. of Biological Chemistry 258:12487-12493 (1983)				
49	Rabson <i>et al.</i> , Nat. Cancer Inst. 495-497 (1969)				
50	Wells <i>et al.</i> , J. of Biological Chemistry 159:1363-1370 (1964)				
51	Nathan <i>et al.</i> , Focus 19:50-51 (1997)				
Examiner: <i>Ann Kr. Chakrabarti</i>					
Date Considered: <i>4/30/02</i>					
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

M 6/04



FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: PRMG-06684	Serial No.: 09/995,912
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: John W. Shultz <i>et al.</i>	
(37 CFR § 1.98(b))		Filing Date: 11/28/01	Group Art Unit: 1634

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite. No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS								
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)		
1	Badet et al., PNAS, 86:8427 (1989)	
2	Wetmur, Crit. Rev. Biochem. and Mol. Biol. 26:227 (1991)	
3	Delcardayre et al., Protein Engineering, 8:261 (1995)	
4	Rahman et al., Anal. Chem., 68:134 (1996)	
5	Shimoyama et al., Clin. Cancer Res. 5:1125 (1999)	
6	GIBCO BRL Catalogue & Reference Guide, AME Reverse Transcriptase System, page 376	No Date Provided
7	Sambrook et al., Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989, pp 7.3-7.4.	
8	Freddie, J. Biol. Chem., 244(14), 3969 (1969)	
9	Promega Corporation, Product Bulletin, M-MLV Reverse Transcriptase	No Date Provided
10	Sarnagadharan et al., J. Virology, 27(3), 568 (1978)	
11	Tewari and Burma, Biochem. Biophys. Res. Comm., 109(1), 256 (1982)	
12	Venkov et al., J. Bacteriology, 108(1), 601 (1971)	
13		
14		
15		
16		
17		
18		

Examiner: Arun K. Chakrabarti	Date Considered: 8/13/03
-------------------------------	--------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

